137 related articles for article (PubMed ID: 38384136)
21. Prognostic significance of senescence-related tumor microenvironment genes in head and neck squamous cell carcinoma.
Lee YC; Nam Y; Kim M; Kim SI; Lee JW; Eun YG; Kim D
Aging (Albany NY); 2023 Dec; 16(2):985-1001. PubMed ID: 38154113
[TBL] [Abstract][Full Text] [Related]
22. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
23. Biomarker Potential of
Ju Y; Zhu F; Fang B
Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
[TBL] [Abstract][Full Text] [Related]
24. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
25. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
Front Genet; 2022; 13():947551. PubMed ID: 35938003
[No Abstract] [Full Text] [Related]
27. A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma.
Zhou C; Shen Y; Jin Y; Shen Z; Ye D; Shen Y; Deng H
Cancer Med; 2022 Dec; 11(24):5097-5112. PubMed ID: 35567376
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor.
Jing F; Wang J; Zhou L; Ning Y; Xu S; Zhu Y
Aging (Albany NY); 2021 Jul; 13(13):17789-17817. PubMed ID: 34247149
[TBL] [Abstract][Full Text] [Related]
29. Head and neck squamous cell carcinoma-specific prognostic signature and drug sensitive subtypes based on programmed cell death-related genes.
Xu C; Xu H; Liu B
PeerJ; 2023; 11():e16364. PubMed ID: 38025757
[TBL] [Abstract][Full Text] [Related]
30. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
31. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
32. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
Cell Oncol (Dordr); 2024 Feb; ():. PubMed ID: 38315286
[TBL] [Abstract][Full Text] [Related]
33. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
[TBL] [Abstract][Full Text] [Related]
34. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
35. Construction of the prognostic signature of alternative splicing revealed the prognostic predictor and immune microenvironment in head and neck squamous cell carcinoma.
Ye F; Wu P; Zhu Y; Huang G; Tao Y; Liao Z; Guan Y
Front Genet; 2022; 13():989081. PubMed ID: 36338975
[No Abstract] [Full Text] [Related]
36. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
[TBL] [Abstract][Full Text] [Related]
37. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an immune-related gene prognostic model for head and neck tumors.
Zhou F; Chen AX; Lv HY; Liang DH; Yu HS
J Biol Regul Homeost Agents; 2021; 35(3):975-986. PubMed ID: 34159769
[TBL] [Abstract][Full Text] [Related]
39. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
40. Subclass-Specific Prognosis and Treatment Efficacy Inference in Head and Neck Squamous Carcinoma.
Zheng Z; Xie W; Chen X; Wang F; Huang L; Li X; Lin Q; Wong KC
IEEE J Biomed Health Inform; 2022 Aug; 26(8):4303-4313. PubMed ID: 35439152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
